Keywords: Cell Therapeutics, FDA decision, Pixantrone, Pixuvir, Appeal, Non-Hodgkin's lymphoma
Cell Therapeutics appeals FDA decision on pixantrone NDA for non-Hodgkin's lymphoma
Article | 06 December 2010
USA-based Cell Therapeutics (Nasdaq and MTA: CTIC) says that it has submitted a formal appeal to the Office of New ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
